Key statistics
On Friday, Exelixis Inc (EXEL:NSQ) closed at 43.92, -11.49% below its 52-week high of 49.62, set on Jun 23, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 42.89 |
|---|---|
| High | 44.05 |
| Low | 42.73 |
| Bid | 43.50 |
| Offer | 44.50 |
| Previous close | 42.70 |
| Average volume | 2.89m |
|---|---|
| Shares outstanding | 259.71m |
| Free float | 253.47m |
| P/E (TTM) | 15.78 |
| Market cap | 11.41bn USD |
| EPS (TTM) | 2.78 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
- Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
- Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
- Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
- Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
- Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
- Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
- Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
More ▼
